Morgan Stanley Issues Positive Forecast for Belite Bio (NASDAQ:BLTE) Stock Price

Belite Bio (NASDAQ:BLTE) had its price target boosted by Morgan Stanley from $191.00 to $201.00 in a research report report published on Tuesday morning,Benzinga reports. They currently have an overweight rating on the stock.

BLTE has been the topic of several other research reports. Cantor Fitzgerald raised their price objective on Belite Bio from $200.00 to $266.00 and gave the stock an “overweight” rating in a research note on Tuesday. Maxim Group set a $200.00 price objective on Belite Bio in a report on Tuesday, December 2nd. HC Wainwright reiterated a “buy” rating and issued a $185.00 price objective on shares of Belite Bio in a research report on Wednesday, January 28th. Mizuho set a $223.00 target price on shares of Belite Bio in a report on Thursday, February 19th. Finally, Bank of America began coverage on shares of Belite Bio in a research note on Monday, January 26th. They issued a “buy” rating and a $195.00 price target on the stock. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $202.33.

Belite Bio Price Performance

Shares of NASDAQ:BLTE opened at $167.88 on Tuesday. The firm’s 50 day simple moving average is $168.93 and its 200 day simple moving average is $123.30. Belite Bio has a fifty-two week low of $49.00 and a fifty-two week high of $200.00. The company has a market capitalization of $6.30 billion, a price-to-earnings ratio of -72.99 and a beta of -1.46.

Belite Bio (NASDAQ:BLTE) last issued its earnings results on Monday, March 2nd. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.18. Equities research analysts expect that Belite Bio will post -1.17 earnings per share for the current year.

Institutional Trading of Belite Bio

A number of hedge funds and other institutional investors have recently modified their holdings of BLTE. China Universal Asset Management Co. Ltd. bought a new position in Belite Bio in the third quarter valued at approximately $370,000. High Net Worth Advisory Group LLC bought a new position in shares of Belite Bio in the third quarter valued at $259,000. Caitong International Asset Management Co. Ltd increased its holdings in Belite Bio by 28,200.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 283 shares of the company’s stock worth $45,000 after buying an additional 282 shares during the last quarter. Jane Street Group LLC bought a new stake in Belite Bio during the fourth quarter worth $5,170,000. Finally, Brooklyn Investment Group acquired a new stake in Belite Bio in the fourth quarter valued at $287,000. Institutional investors and hedge funds own 0.53% of the company’s stock.

Key Belite Bio News

Here are the key news stories impacting Belite Bio this week:

• Positive Sentiment: Multiple brokerages raised targets and ratings — Cantor Fitzgerald to $266 (overweight), Morgan Stanley to $201 (overweight), and HC Wainwright to $200 (buy), implying high upside from current levels and reflecting bullish analyst conviction. Analyst Price Target Raises
• Positive Sentiment: Belite reported a Q4 beat: EPS of ($0.38) vs. consensus ($0.56), which reduces near-term execution risk and supports valuation upgrades. Earnings Results & Call
• Positive Sentiment: Company update targets a Q2 2026 NDA submission for its Stargardt program and plans $200M–$250M commercialization spend; management also reports rising cash reserves — this is a material development for future revenue potential and commercialization planning. NDA Timeline & Commercialization Plan
• Neutral Sentiment: Belite will participate in investor conferences (Leerink Global Healthcare), and transcripts/slides from the earnings call are available — helpful for due diligence but not immediate stock-moving by themselves. Conference Participation
• Neutral Sentiment: Multiple earnings-call transcripts and the company’s preliminary Q4/full-year press release and slide deck were published — useful context for analysts and investors. Press Release & Slides
• Neutral Sentiment: Short-interest entries published appear inconsistent (reports show “0 shares” and NaN changes, days-to-cover 0.0) — the data looks erroneous, creating unclear signal regarding bearish positioning. Investors should watch reliable short-interest filings for any true build in shorts.
• Negative Sentiment: Despite the positive fundamental and analyst news, the stock is down today — likely reflection of profit-taking after a recent run toward the 1-year high, or broader market/sector weakness; this intraday decline may be temporary unless follow-through negative news appears.

Belite Bio Company Profile

Belite Bio, Inc (NASDAQ: BLTE) is a clinical-stage biotechnology company focused on discovering and developing small molecule therapeutics for metabolic and inflammatory diseases. Leveraging a proprietary drug-discovery platform, the company aims to address conditions such as nonalcoholic steatohepatitis (NASH) and obesity by targeting pathways involved in fibrosis, inflammation and metabolic regulation.

Belite Bio’s pipeline includes multiple candidates in preclinical and early clinical development stages.